Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Bluejay Diagnostics Q3 2026 Results: Net Loss of $2.01M, Loss Widens

Bluejay Diagnostics reported a net loss of $6.26 million for the nine months ended September 30, 2026, compared to $5.42 million in the prior year period. The company strengthened its cash position to $7.38 million through private placements and warrant exercises, while continuing to invest heavily in research and development for its diagnostic platform.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-2.0-1.6
EPS (diluted, $ a share)$-1.72$-16.92

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: BJDX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Bluejay Diagnostics, Inc.: key numbers

Share price
$2.29Close, Nov 16
Market cap
$2.56M
Shares outstanding
1.12MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Bluejay Diagnostics, Inc.

All →
4:07 PM ET 8-K
Business Update

Bluejay Diagnostics Business Update

Bluejay Diagnostics provided a corporate update for Q3 2026, highlighting the completion of enrollment for its SYMON-II clinical study and the establishment of an alternative manufacturing site ahead of schedule. The company reported a cash balance of $7.38 million and targets an FDA 510(k) submission for its Symphony IL-6 platform in the first half of 2027.

6:30 AM ET 8-K
Reverse Stock Split

Bluejay Diagnostics Reverse Stock Split

Bluejay Diagnostics implemented a 1-for-4 reverse stock split of its common stock, effective November 3, 2026. The split reduces the number of outstanding shares from approximately 4.47 million to 1.12 million to maintain compliance with Nasdaq listing requirements. Trading will continue under the ticker 'BJDX' with a new CUSIP number.

9:10 AM ET 8-K
Business Update

Bluejay Diagnostics Business Update

Bluejay Diagnostics achieved a critical contractual milestone under its license agreement with Toray Industries by establishing a manufacturing site for its Symphony cartridges at SanyoSeiko Co. in Japan. This milestone was reached ahead of the October 23, 2026 deadline and is part of a broader strategy to build a resilient supply chain alongside its U.S. manufacturing partner, ALURIS Sciences.

Counterparty
Toray Industries, Inc.
9:04 AM ET 8-K
Clinical Trial Data

Bluejay Diagnostics Clinical Trial Data

Bluejay Diagnostics announced baseline clinical characteristics from its SYMON-II clinical validation study, which is evaluating the Symphony IL-6 Test for mortality risk in sepsis patients. The study includes 777 evaluable patients with an 18% mortality rate, providing a diverse dataset to support the company's planned regulatory submission. The data showed that non-survivors had higher baseline illness severity, with septic shock present in 56.4% of that group.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.